Confo Therapeutics to appoint John Berriman as Chairman of the Board
Brussels, Belgium: 15 December 2016 - Confo Therapeutics, an emerging drug discovery company, today announced the appointment of John Edward Berriman as non-executive director and chairman of the board of directors, starting December 21.
Commenting on the board appointment, Dr. Cedric Ververken, CEO, said: "We are delighted to have attracted someone of John Berriman's calibre to serve as Chairman of our Company. John has a very impressive track record in founding, financing and growing biotech companies and his appointment is a huge asset to Confo Therapeutics as it further transitions from a technology to a drug discovery company."
More info on Confo Therapeutics' website.
Next > Ogeda announces fezolinetant as INN and issuance of US patent for ESN364
Previous > Michiel Boersma appointed as Chairman of Avantium’s Supervisory Board